Solventum Corporation
SOLV - NYSE - $73.38 ▲ +%2.41
-
Earnings Thu 6 Aug

Solventum opens the
books on Thursday evening.

5 analysts' median target is $93[FMP target], stock is $73, +26.1% upside potential. After Q1 +9.6% EPS beat[FMP earnings], the stock moved +2.8%.

↓ summary below
Quick Take - in 40 seconds
A
BUY Council 5/6 - Moonshot 37

A = MoonshotScore 37[9-pillar formula] + Council 5/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q1 consensus: revenue $2.2B[FMP est], EPS $1.93[FMP est]. 8 consecutive quarters of beat[FMP earnings].

Detailed analysis below ↓
$1.93 EPS Estimate Last year $1.48 - +14% YoY YoY
8 Beat Streak Expectations beaten consecutively for the last 8 quarters

Q1 EPS +9.6% beat[FMP] but the stock +2.8% D+1[FMP D+1]. Wayde McMillan promised $84.0M CapEx + a sequential decline in Q1 during the Q1 earnings call[Wayde McMillan capex transcript].

Watchlist

3 metrics stand out this quarter.

$100 million Investor Focus

ERP Cutover Impact

ERP_cutover_impact

The company anticipates over $100 million of sales timing benefit in Q2 due to the upcoming ERP cutover in the U.S., with most of it expected to reverse in Q3.

"We estimate over $100 million of sales timing benefit in Q2 that we expect will reverse in 2026, mostly in Q3."

- Wayde McMillan, CFO - Q1 FY26 Earnings Call - May 5, 2026
$500 million Investor Focus

Transform For The Future

transform_for_the_future

The company's Transform for the Future program is a multiyear $500 million savings program aimed at freeing up resources to invest for the long term by streamlining systems, increasing automation, and optimizing its global footprint.

"As a reminder, our Transform for the Future program is a multiyear $500 million savings program. It is our way of proactively reshaping our operating structure while freeing up resources to invest for the long term."

- Bryan Hanson, CEO - Q1 FY26 Earnings Call - May 5, 2026
- Investor Focus

Acera Acquisition

acera_acquisition

The acquisition of Acera is a proof point of the company's growth strategy, providing entry into the fast-growth acute care synthetic tissue space and fitting perfectly into its existing advanced wound care infrastructure.

"With Acera, it opens the door to the fast-growth acute care synthetic tissue space and really slots perfectly into our advanced wound care infrastructure."

- Bryan Hanson, CEO - Q1 FY26 Earnings Call - May 5, 2026

Stock Expert AI - Methodology

Do our 9 pillars, 7 perspectives, and Munger lens point in the same direction?

MoonshotScore 37 / 100

9-pillar methodology. R&D Intensity and Price Momentum strong. Revenue Growth weak.

How is it calculated? ->
Revenue Growth0.0Q1 vs Q2: growth negative (-7.1%, contraction)
Gross Margin5.0Q1: high margin (54.7%)
Operating Leverage0.0op margin weak (4.0%, under pressure)
Cash Runway3.0FCF negative ($-0.3B, external financing needed)
R&D Intensity7.0balanced R&D investment (8.9%)
Price Momentum7.0RSI 66.7 positive momentum, 50d above
News Sentiment4.0mixed (43% buy)
Council Score 5 / 6 Bullish

6 investor frameworks. 5 bullish (Ray Dalio, Ken Griffin, Klarman, Buffett, Munger), 0 bearish (none), 1 neutral (Jim Simons).

How is it calculated? ->
Ray Dalio macro - target upside +26.1%
Ken Griffin flow - 50d MA above
Jim Simons quant - RSI 67
Klarman value - target upside +26.1%
Buffett quality - ROE score 5/5
Munger valuation - target upside +26.1%
Munger's Mindset character & balance sheet lens
Undervalued

Quality business, discounted price.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyStrong
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
66.7 RSI 66.7 positive momentum, 50d above
MACD
+8.40 price above 50d - support positive
50d MA
$68 stock 8.4% above - short-term support
200d MA
$74 stock 0.6% below - long-term pressure
Volume (10d)
+5% increase - pre-earnings positioning
Resistance
$93
Analyst median target - upgrade trigger if broken
Current
$73
Pre-earnings position
Support
$63
Invalidation - close below this is a technical breakdown
Pattern
Range
$63-$93 band - earnings breakout/breakdown trigger

Past Performance

Solventum beat expectations in the last 8 quarters.

BEAT
Q2 FY25
$1.69 vs $1.45 est - +2.0%
BEAT
Q3 FY25
$1.50 vs $1.43 est - +7.9%
BEAT
Q4 FY25
$1.57 vs $1.50 est - -3.6%
BEAT
Q1 FY26
$1.48 vs $1.35 est - +2.8%

Q1 (May 5, 2026): EPS $1.48 vs $1.35 est[FMP], +9.6% beat. D+1 movement: +2.8%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $1.87 (no guidance)

Q1: EPS $1.48 vs $1.35 beat[FMP], stock +2.8% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $84.0M[FMP cashflow]. Q1 op margin 4.0%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q1 EPS > $1.93 + CapEx discipline
Threshold: EPS > $1.93[FMP est].
Target: Break above median target $93[FMP target]; high target $100[FMP] upper bound.
Scenario B - In-Line
EPS approx $1.93 + CapEx < $84.0M
Threshold: EPS approx $1.93[FMP est], Q1 CapEx < $84.0M[FMP].
Target: Consolidation in the band between current $73[FMP] and median $93[FMP].
Scenario C - Miss
EPS < $1.87 or CapEx >= $84.0M
Threshold: EPS < $1.87[FMP estx0.97].
Target: Current $73 below SMA200 $74[FMP], if rejection continues, $63[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 5 analysts say?

Wall Street Consensus
$93
12-month median target price (+26.1% upside potential)
6
BUY
6
HOLD
2
SELL
Risk Management
$63
Invalidation level - critical support threshold
$68 - 50-day MA (above, +8.4%)
$74 - 200-day MA (below, -0.6%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - SOLV Q1 FY27
A

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q1 EPS threshold $1.93[FMP], CapEx threshold "below $84.0M"[Wayde McMillan]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Try Pro free for 14 days SOLV dossier ->

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Aug 6, 2026EARNINGSQ1 FY27 results (after market close) + earnings call
Aug 7, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Sep 20, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Nov 6, 2026EARNINGSQ2 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the SOLV earnings preview cover?

This SOLV (SOLV) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in SOLV earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.